Repertoire Immune Medicines, a newly launched company working to surface the power of the immune system to prevent and cure disease, received an investment from the JDRF T1D Fund.
The amount of the deal was not disclosed.
The company intends to use the funds to utilize its core platforms to discover new antigens and T cell receptors in hopes of advancing the development of treatments and cures for T1D.
Led by John Cox, Chief Executive Officer, Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.